cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

PLEASANTON, Calif., July 30, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® prime Pre-analytical System to improve efficiency in molecular diagnostics ...

Roche’s point-of-care polymerase chain reaction (PCR) test for pertussis (whooping cough) and other Bordetella infections has ...

HERLEV, Denmark , May 8, 2025 /PRNewswire/ -- Nordic Bioscience announces that its PRO-C3 test is launched by Roche Diagnostics on their cobas analysers. The Roche Elecsys® PRO-C3, used with the ADAPT ...

PLEASANTON, Calif., Oct. 29, 2020 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of expanded claims for the cobas® EGFR Mutation ...

Roche launched a relatively more compact addition to its mainstay cobas molecular diagnostic lineup with instruments that aim to bring automated testing to laboratories of all sizes. Roche is ...

Swiss biotech company Roche announced on December 21, 2015 that the FDA has approved the Cobas® 6800 and 8800 Systems from its Pleasanton, California-based Roche Molecular Diagnostics (RMD) for the ...

Early diagnosis can reduce the risk of complications and severe disease in vulnerable groups such as infants and the elderly, by enabling faster, more precise care decisions.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the cobas® KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to ...